Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(158 productos)
- Bcr-Abl(113 productos)
- EGFR(598 productos)
- FAK(72 productos)
- FLT(90 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(182 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(90 productos)
- Src(81 productos)
- Syk(37 productos)
- Trombina(53 productos)
- VDA(2 productos)
- VEGFR(250 productos)
Mostrar 6 subcategorías más
Se han encontrado 2040 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DBMB
CAS:DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.Fórmula:C24H22N4OForma y color:SolidPeso molecular:382.458BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Fórmula:C26H36N6O3Forma y color:SolidPeso molecular:480.6JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96Flonoltinib sulfate
CAS:Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.Fórmula:C25H36FN7O5SForma y color:SolidPeso molecular:565.661TX2-121-1
CAS:TX2-121-1 targets HER3 for proteasome-mediated degradation to inhibit HER3-dependent signalling and growth.Fórmula:C42H52N8O3Pureza:98%Forma y color:SolidPeso molecular:716.91CEP-14083
CAS:<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Fórmula:C31H30N6O2Forma y color:SolidPeso molecular:518.61E6201
CAS:E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).Fórmula:C21H27NO6Forma y color:SolidPeso molecular:389.44Paeoniflorin-6′-O-benzene sulfonate
CAS:Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.Fórmula:C29H32O13SForma y color:SolidPeso molecular:620.622SJ-C1044
CAS:<p>SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.</p>Fórmula:C25H14F7N7OForma y color:SolidPeso molecular:561.41Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Fórmula:C19H20FN5OSForma y color:SolidPeso molecular:385.458CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Fórmula:C18H14N4Forma y color:SolidPeso molecular:286.331HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Fórmula:C26H25F2N9O3Forma y color:SolidPeso molecular:549.53FGFR2/3-IN-2
CAS:<p>FGFR2/3-IN-2 (compound 10) is an orally active inhibitor targeting FGFR2 and FGFR3. It exhibits IC50 values of 3.7 nM for FGFR2 and 31.2 nM for FGFR3, with a pre-incubation time of 1 hour. FGFR2/3-IN-2 demonstrates selectivity over FGFR1/4 and other kinases, and does not cause diarrhea or increased serum phosphate in vivo. In the SNU-16 gastric cancer model, FGFR2/3-IN-2 can induce tumor stasis or regression.</p>Fórmula:C29H23FN6O3Forma y color:SolidPeso molecular:522.53EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424Gamendazole
CAS:Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.Fórmula:C18H11Cl2F3N2O2Pureza:98%Forma y color:SolidPeso molecular:415.19EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Fórmula:C16H15N3OSForma y color:SolidPeso molecular:297.375EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Fórmula:C27H19ClFN3OForma y color:SolidPeso molecular:455.91Ifebemtinib tosylate
CAS:Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor with anti-tumor properties. It inhibits FAK autophosphorylation in prostate cancer cells and suppresses spheroid formation and in situ tumor growth in vivo. Ifebemtinib (tosylate) is applicable in cancer research, including studies on solid tumors, breast cancer, and malignant pleural mesothelioma.Fórmula:C35H36F4N6O7SForma y color:SolidPeso molecular:760.76CEP-7055
CAS:CEP-18770: oral proteasome inhibitor; blocks NF-kappaB; may cause cancer cell apoptosis; less toxic than bortezomib in normal cells.Fórmula:C32H35N3O4Forma y color:SolidPeso molecular:525.64
